1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Pfizer Has Tafamidis Data In Hand, But Market Development Still A Challenge

 
• By Joseph Haas

Unveiling its Phase III data showing both an all-cause mortality and cardiovascular hospitalization benefit, Pfizer thinks it can bring dramatic improvement in therapy for transthyretin cardiomyopathy.

Anatomy of Human Heart

Phase III data showing tafamidis can reduce all-cause mortality and cardiovascular-related hospitalization has Pfizer Inc. anticipating a potential rare disease blockbuster, but it conceded Aug. 27 that first it will have make substantial efforts to build the market in transthyretin cardiomyopathy (ATTR-CM).

Analysts swooned at the data showing a 30% reduction in all-cause mortality and 32% decrease in cardiovascular-related hospitalization at 30...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

ESMO 25: Tolerability Raised As Exelixis STELLAR-303 Study Still Needs To Mature

 
• By Alexandra Shimmings

Exelixis’s novel kinase inhibitor zanzalintinib has shown promise in a metastatic colorectal cancer population but some experts want to see more data before passing judgement on whether it can become a new chemotherapy-free treatment option for these patients.

Sanofi’s Inhibrx-Acquired Rare Disease Therapy Clears Phase II Hurdle

 
• By Manas Mishra

Efdoralprin alfa, which was acquired through Inhibrx, has met the endpoints of a Phase II trial for alpha-1 antitrypsin deficiency.

How To Score A Win With Real-World Evidence In India

 
• By Vibha Ravi

Bharat Serums showed it’s possible to score a regulatory win with real-world evidence (RWE) studies in India when it ran one leading to a label expansion for its mAb trinbelimab. As cell and gene therapies and rare disease drugs gain currency, sponsors could look at takeaways from the RhYTHM study.

Summit Presses Ahead With Ivonescimab Filing Despite Approval Doubts

 
• By Andrew McConaghie

Frontrunner believes it can gain a first approval in EGFR+ lung cancer, even though the FDA recently raised the bar on overall survival.

More from R&D

China’s Next Wave Is First-In-Class Innovation

 
• By Jessica Merrill

Drug development in China was a discussion topic at the BioFuture conference as the country’s R&D investments begin to deliver first-in-class medicines.

Neuphoria To Look At Strategic Options After BNC210 Fails In Social Anxiety

 
• By Alaric DeArment

Neuphoria said that its Phase III trial of BNC210 in social anxiety disorder did not meet the primary or secondary endpoints, but its PTSD program will continue.

ESMO 25: Ovarian Cancer Data Validates Tubulis ADC Platform

 
• By Kevin Grogan

Positive first-in-human data for TUB-040 represent "a momentous milestone" for the German biotech, according to its CEO Dominik Schumacher.